# FEDERAL ELECTION COMMISSION

# **Sunshine Act Notice**

## CANCELLATION OF PREVIOUSLY ANNOUNCED MEETINGS:

Tuesday, December 4, 2001, 10 a.m.; meeting closed to the public.

Thursday, December 6, 2001, 10 a.m.; meeting open to the public.

DATE & TIME: Thursday, December 6, 2001 at 10 a.m.

**PLACE:** 999 E Street, NW, Washington, DC.

**STATUS:** This meeting will be closed to the public.

#### ITEMS TO BE DISCUSSED:

Compliance matters pursuant to 2 U.S.C. § 437g.

Audits conducted pursuant to 2 U.S.C. § 437g, § 438(b), and title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

**PERSON TO CONTACT FOR INFORMATION:** M. Ron Harris, Press Officer, telephone: (202) 694–1220.

## Mary W. Dove,

Secretary of the Commission. [FR Doc. 01–29790 Filed 11–27–01; 2:44 pm] BILLING CODE 6715-01-M

FEDERAL HOUSING FINANCE BOARD

#### Sunshine Act Meeting

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 66 FR 57967, November 19, 2001.

**PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING:** 10:00 a.m., Wednesday, November 28, 2001.

**CANCELLATION OF THE MEETING:** Notice is hereby given of the cancellation of the Board of Directors meeting scheduled for November 28, 2001.

**CONTACT PERSON FOR MORE INFORMATION:** Elaine L. Baker, Secretary to the Board, (202) 408–2837.

#### James L. Bothwell,

Managing Director. [FR Doc. 01–29713 Filed 11–26–01; 4:15 pm]

BILLING CODE 6725-01-P

# FEDERAL HOUSING FINANCE BOARD

# Sunshine Meeting; Notice Announcing an Open Meeting of the Board

**TIME AND DATE:** 10 A.M., Wednesday, December 5, 2001.

**PLACE:** Board Room, Second Floor, Federal Housing Finance Board, 1777 F Street, N.W., Washington, DC 20006.

**STATUS:** The entire meeting will be open to the public.

#### MATTERS TO BE CONSIDERED DURING PORTIONS OPEN TO THE PUBLIC:

- Final Rule: Unsecured Credit Limits for the Federal Home Loan Banks
- Waiver of Compliance with the Minimum Liquidity Requirements of § 932.8 and the Unsecured Credit Limits of § 932.9
- Proposed Rule: Amendments to the Affordable Housing Program

**CONTACT PERSON FOR MORE INFORMATION:** Elaine L. Baker, Secretary to the Board, (202) 408–2837.

# James L. Bothwell,

Managing Director. [FR Doc. 01–29773 Filed 11–27–01; 2:08 pm] BILLING CODE 6725–01–P

# FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

#### **Sunshine Act Meeting**

**TIME AND DATE:** 10 a.m. (EST), December 10, 2001.

**PLACE:** 4th Floor, Conference Room 4506, 1250 H Street, NW., Washington, DC.

#### STATUS; Open.

#### MATTERS TO BE CONSIDERED:

- 1. Approval of the minutes of the November 13, 2001, Board member meeting.
- 2. Thrift Savings Plan activity report by the Executive Director.
- 3. Review of KPMG LLP audit reports:
  - (a) Thrift Savings Plan Billing Process at the Untied States Department of Agriculture, National Finance Center.
  - (b) Thrift Savings Plan Annuity Operations at the Metropolitan Life Insurance Company.

CONTACT PERSON FOR MORE INFORMATION:

# Thomas J. Trabucco, Director, Office of External Affairs, (202) 942–1640.

Dated: November 27, 2001.

#### Elizabeth S. Woodruff,

Secretary to the Board, Federal Retirement Thrift Investment Board.

[FR Doc. 01–29822 Filed 11–29–01; 3:53 pm] BILLING CODE 6760–01–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Antiviral Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

# ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Antiviral Drugs Advisory Committee.

*General Function of the Meeting*: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 12, 2001, from 8:15 a.m. to 5:15 p.m.

*Location*: Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave., Bethesda, MD.

*Contact*: Tara P. Turner, Center for Drug Evaluation and Research (HFD– 21), Food and Drug Administration, 5600 Fishers Lane (for express delivery 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, e-mail: TurnerT@cder.fda.gov, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area), code 12531. Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will be updated on the approval of biologics license application supplement 103949/ 5002, PEG–INTRON (peginterferon alfa-2b) powder for injection, Schering Corp., indicated for use alone or in combination with Rebetol (ribavirin, USP), for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age.

Procedure: On December 12, 2001, from 8:15 a.m. to 12:15 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 5, 2001. Oral presentations from the public will be scheduled between approximately 10 a.m. and 11 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before December 5, 2001, and submit a brief statement of the general nature of the evidence or arguments

they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations*: On December 12, 2001, from 1:15 p.m. to 5:15 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)).

FDA regrets that it was unable to publish this notice 15 days prior to the December 12, 2001, Antiviral Drugs Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Antiviral Drugs Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 21, 2001.

#### Bonnie H. Malkin,

Acting Senior Associate Commissioner for Communications and Constituent Relations. [FR Doc. 01–29738 Filed 11–27–01; 11:15 am]

BILLING CODE 4160-01-S

#### INTERNATIONAL TRADE COMMISSION

[Investigations Nos. 731–TA–929–931 (Final)]

# Silicomanganese From India, Kazakhstan, and Venezuela

**AGENCY:** United States International Trade Commission.

**ACTION:** Scheduling of the final phase of antidumping investigations.

**SUMMARY:** The Commission hereby gives notice of the scheduling of the final phase of antidumping investigations Nos. 731–TA–929–931 (Final) under section 735(b) of the Tariff Act of 1930 (19 U.S.C. 1673d(b)) (the Act) to determine whether an industry in the United States is materially injured or threatened with material injury, or the establishment of an industry in the United States is materially retarded, by reason of less-than-fair-value imports from India, Kazakhstan, and Venezuela of silicomanganese, provided for in subheading 7202.30.00 of the Harmonized Tariff Schedule of the United States (HTS).12

For further information concerning the conduct of this phase of the investigations, hearing procedures, and rules of general application, consult the Commission's rules of practice and procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A and C (19 CFR part 207).

# **EFFECTIVE DATE:** November 9, 2001.

FOR FURTHER INFORMATION CONTACT: Woodley Timberlake (202-205-3188), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202-205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (http:// www.usitc.gov). The public record for these investigations may be viewed on the Commission's electronic docket (EDIS-ON-LINE) at http:// dockets.usitc.gov/eol/public.

#### SUPPLEMENTARY INFORMATION:

#### Background

The final phase of these investigations is being scheduled as a result of affirmative preliminary determinations by the Department of Commerce that imports of silicomanganese from India, Kazakhstan, and Venezuela are being sold in the United States at less than fair value within the meaning of section 733 of the Act (19 U.S.C. 1673b). The investigations were requested in a petition filed on April 6, 2001, by Eramet Marietta, Inc. (Marietta, OH) and the Paper, Allied-Industrial, Chemical and Energy Workers International Union, Local 5–0639.

<sup>2</sup> Some silicomanganese may also be entered under HTS statistical reporting number 7202.99.5040. The merchandise covered by the scope of these investigations includes all silicomanganese (excluding the aforementioned low-carbon silicomanganese), regardless of its tariff classification.

#### Participation in the Investigations and Public Service List

Persons, including industrial users of the subject merchandise and, if the merchandise is sold at the retail level, representative consumer organizations, wishing to participate in the final phase of these investigations as parties must file an entry of appearance with the Secretary to the Commission, as provided in § 201.11 of the Commission's rules, no later than 21 days prior to the hearing date specified in this notice. A party that filed a notice of appearance during the preliminary phase of the investigations need not file an additional notice of appearance during this final phase. The Secretary will maintain a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigations.

#### Limited Disclosure of Business Proprietary Information (BPI) Under an Administrative Protective Order (APO) and BPI Service List

Pursuant to § 207.7(a) of the Commission's rules, the Secretary will make BPI gathered in the final phase of these investigations available to authorized applicants under the APO issued in the investigations, provided that the application is made no later than 21 days prior to the hearing date specified in this notice. Authorized applicants must represent interested parties, as defined by 19 U.S.C. 1677(9), who are parties to the investigations. A party granted access to BPI in the preliminary phase of the investigations need not reapply for such access. A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO.

#### Staff Report

The prehearing staff report in the final phase of these investigations will be placed in the nonpublic record on January 10, 2002, and a public version will be issued thereafter, pursuant to § 207.22 of the Commission's rules.

#### Hearing

The Commission will hold a hearing in connection with the final phase of these investigations beginning at 9:30 a.m. on January 24, 2002, at the U.S. International Trade Commission Building. Requests to appear at the hearing should be filed in writing with the Secretary to the Commission on or before January 17, 2002. A nonparty who has testimony that may aid the Commission's deliberations may request permission to present a short statement at the hearing. All parties and

<sup>&</sup>lt;sup>1</sup>For purposes of these investigations, the Department of Commerce has defined the subject

merchandise as "all forms, sizes and compositions of silicomanganese, except low-carbon silicomanganese, including silicomanganese, including silicomanganese briquettes, fines and slag." Silicomanganese generally contains by weight not less than 4 percent iron, more than 30 percent manganese, more than 8 percent silicon and not more than 3 percent phosphorous. Low-carbon silicomanganese excluded from the scope of these investigations is a feroalloy with the following chemical specifications: minimum 55 percent manganese, minimum 27 percent silicon, minimum 4 percent iron, maximum 0.10 percent phosphorus, maximum 0.10 percent carbon and maximum 0.05 percent sulfur.